KU ASH 2018 Review: Current Updates in Hematologic Diseases
Avatar

ASH December 2018- Aggressive Lymphomas: Recent Approvals and Promising Studies

By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Anusha Vallurupalli
By KU ASH 2018 Review: Current Updates in Hematologic Diseases FEATURING Anusha Vallurupalli
150 views
March 8, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
13:16
ASH 2022 Conference Coverage

Experts Discuss Key Updates in CLL

Feat. S. O'Brien, C. Coombs
27:14
2024 Clinical Case Studies

Clinical Case Review: Cutaneous T Cell Lymphoma in the Patch Test Cl…

Feat. J. Murase
10:35
Alan Skarbnik

Learnings From the ELEVATE-TN Phase 3 Trial: Acalabrutinib+/-Obinutu…

04:14
ecancer

ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for…

Feat. J. Brown
18:04
Seema Bhat

Zanubrutinib for the Treatment of CLL: Learnings From ALPINE, SEQUOI…

06:53
Fred Hutchinson Cancer Center

Surveying Safety and Efficacy Data in R/R CLL: ALPINE and ELEVATE-RR…

Feat. M. Shadman
13:27
Benjamin Heyman

Recent Updates in CLL

16:43
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient

Advances in CLL and Mantle Cell Lymphoma

Feat. E. Chong
17:23
Current Challenges in Hematology

2023 Updates on Sequencing in CLL

Feat. L. Scarfò
09:33
Adam Kittai

Chemo-Free Approaches in the Frontline Setting of CLL: Treatment Goa…

12:06
Catherine Coombs

New BTKi in CLL

24:11
Jennifer Brown

State of the Art & Next Questions: CLL

14:21
Masterclasses in Dermatology

Comorbidities of Psoriasis and PsA

Feat. J. Cohen
09:33
City of Hope

Assessing Comorbidities in CLL

Feat. A. Danilov
09:35
UNC Lineberger Comprehensive Cancer Center

The Importance of Molecular Testing for Therapeutic Decision Making …

Feat. C. Coombs
09:12
Julia Erin Wiedmeier-Nutor

Del(17p) and TP53 Mutations in CLL and MM: Overview and Treatment Re…

43:53
PleXus Communications

Clinical Practices for Optimizing the Use of BTK Inhibitors for the …

Feat. M. Davids
67:23
University of Louisville

CAR T-Cell Therapy has Redefined the Treatment Algorithm for Relapse…

Feat. M. Kharfan-Dabaja
08:19
RWCS

RWCS 2021 Highlights on Biologics/tsDMARDs: What Are the Commonly Co…

Feat. A. Kavanaugh, J. Cush
07:00
8th Eurasian Hematology Oncology Summit

MRD in CLL: What Were the Changes and Issues Over the Years? Is This…

Feat. R. Foa